For access to the current Concept Form template see 'Downloads' at the bottom of this page.
New v5 template is now available...
The REQUITE Resource
The centralised REQUITE database includes:
(A) epidemiological/clinical data, cancer treatment, CTCAE v4.0 based toxicity data, patient reported outcome, quality of life (EORTC C30, MFI), and physical activity ( GPAQ), non-genetic risk factors, new events and survival data, and breast photos of breast cancer patients;
(B) full dosimetry/physics data (DVH, DICOM);
(C) genotype data from the Illumina Infinium OncoArray 500K beadchip and imputation of genotypes using 1000 Genomes Project Phase 3 as reference panel (Haplotype release date October 2014, for chromosomes 1 to 22, August 2015 for chromosome X; https://goo.gl/jtvyfF);
(D) radiation induced lymphocyte assay (RILA) data.
In addition, the centralised quality-assured biobank at CIGMR, University of Manchester, UK, contains REQUITE patients’ DNA and PaxGene blood samples available for future biomarker assays. All the laboratory, data and management processes are conducted under ISO9001:2008. DNA extraction was automated (using a magnetic bead based method), measured via nanodrop and normalised to 100ug/µl and plated before storage in temperature monitored -80°C freezers. The biobank comprises DNA samples from breast, prostate and lung cancer patients as follows:
- Breast: 2,069
- Prostate: 1,809
- Lung: 562
Access to the Resource
This comprehensive database and linked biobank are a valuable resource for future research and the REQUITE consortium are keen to promote FAIR access (see REQUITE Data Management Plan v2.0). Requests for access to data and/or samples are made via a Concept Form and are reviewed by the REQUITE Publications Committee. Once approval is granted, a personal user account will be created on the LabKey system providing customised access to the approved aspects of data. A data sharing agreement may also be required. A spreadsheet detailing concept forms already reviewed by the Publications Committee is given below.
Funding for the five year REQUITE project ended on 30th September 2018. In order to support continued maintenance of the database and biobank beyond this date, and to facilitate continued access to researchers, the REQUITE Steering Committee has approved a tiered cost recovery model. Contact REQUITE (email@example.com) for more information on pricing.
Extract from the REQUITE Publications Policy v2 (13FEB18)
New research projects can be proposed at any time via submission of a Concept Form. The Publications Committee encourages submissions from researchers associated with REQUITE and also external investigators who wish to make use of this resource. Following open discussion and review by the Publications Committee, a decision will be made by consensus as to whether the project should be taken forward.
Once a proposal for a project is accepted, it will be signed off and posted to the REQUITE SharePoint. Additional investigators/ study groups will be given the opportunity to join in and contribute to the proposed project, for example by playing a role in data analysis or contributing data. Study groups that choose to sign up for a given project are agreeing to submit their data by a given deadline, and if that data passes quality control assessment and is included in the final analysis they can nominate up to three co-authors on the paper.
The lead investigator who proposes the project will undertake the analysis and write up the work themselves, or they can nominate others to do it. The lead investigator will be responsible for developing a projected time frame for manuscript preparation, however, it should generally be expected that analysis and write up of the draft manuscript is completed within six months of the data submission deadline.
The draft manuscript must be circulated before submission, giving at least three weeks to complete review. This will ensure there is sufficient time for all contributing study groups to suggest edits and decide co-authors and affiliations. Any errors in analysis or interpretation will be identified by other experts in the field during this review phase. As soon as this is complete the lead author can submit to the journal.